Quick Answer
Praxis Precision Medicines, Inc. reported Research And Development Expense of $267.12 million for the year ending 2025.
- Praxis Precision Medicines, Inc. showed an increase of +75.3% in Research And Development Expense from 2024 to 2025.
- This data is from Praxis Precision Medicines, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $9.35 million | Q1 2020: $6.87 million | Q2 2020: $9.05 million | Q3 2020: $12.79 million | Q1 2021: $17.93 million | Q2 2021: $25.68 million | Q3 2021: $33.14 million | Q1 2022: $52.65 million | Q2 2022: $43.62 million | Q3 2022: $30.44 million | Q1 2023: $25.50 million | Q2 2023: $25.61 million | Q3 2023: $17.26 million | Q1 2024: $26.98 million | Q2 2024: $27.26 million | Q3 2024: $41.88 million | Q1 2025: $60.81 million | Q2 2025: $63.01 million | Q3 2025: $65.80 million.
- Over the full 7 years of available data (2019 to 2025), Praxis Precision Medicines, Inc.'s Research And Development Expense has grown by 803.7%.
- Historical annual values: Fiscal year 2025: $267.12 million | Fiscal year 2024: $152.41 million | Fiscal year 2023: $86.77 million | Fiscal year 2022: $155.04 million | Fiscal year 2021: $120.26 million | Fiscal year 2020: $44.98 million | Fiscal year 2019: $29.56 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: